Slide 1: Developing next generation solutions to address hearing disorders
Developing next generation solutions to address hearing disorders Restore Treat Prevent Euronext Growth: ALSEN
Slide 2: Disclaimer
Disclaimer This document has been prepared by Sensorion (the “Company”) and is provided for information This document contains certain forward-looking statements. These statements are not guarantees of purposes only. This document does not purport to contain comprehensive or complete information the
Slide 3: Sensorion at a glance
Sensorion at a glance The inner-ear specialist: building leadership across the full spectrum of hearing loss disorders. Expertise Lead program Second asset Shareholder base Inner-ear know-how SENS-601 SENS-401 Blue-chip healthcare specialist investors Inner-ear drug development Gene therapy candidat
Slide 4: Pipeline: leading player in GJB2
Pipeline: leading player in GJB2 Program Preclinical Phase I/II Phase III Next steps CTA approved in France; submitted in Canada. US IND GJB2 (DFNB1A) HL: and Australia CTA submission congenital onset (YE 2026). First patient dosing in France targeted by early SENS-601 * 2027 GJB2 (DFNB1A) HL: Precl
Slide 5: Recent highlights and upcoming milestones
Recent highlights and upcoming milestones ✓ Achieved Expected ✓ January 2026 ✓ June 2026 ✓ August 2026 Expected Q4 2026 → 2027 €60 million financing New Chief Executive Officer CTA cleared in France; US IND, Australia CTA and completed appointed submitted in Canada first patient dosed €20m from Sano
Slide 6: RESTORE
RESTORE SENS-601 for GJB2-related congenital hearing loss 6
Slide 7: Initial market opportunity
Initial market opportunity Widespread newborn screening and advances in early GJB2 (DFNB1A) HL: congenital onset genetic testing continue to improve the identification Illustrative management estimate and characterization of children with GJB2-related hearing loss. Births per year in the US, EU4 and
Slide 8: The inner ear as a gene therapy target
The inner ear as a gene therapy target 01 Direct local administration to target cells, with limited biodistribution outside the inner ear 02 Immunologically protected by the blood–labyrinth barrier 03 Low volume and low viral particle count versus systemic approaches 04 Durable activity from a singl
Slide 9: The role of Connexin 26 (Cx26) in the cochlea
The role of Connexin 26 (Cx26) in the cochlea Cx26, encoded by GJB2, is the predominant connexin in the cochlea, where it forms gap junctions between non-sensory supporting cells. Those gap junctions enable metabolite exchange and potassium recycling that sustain the electrochemical gradient driving
Slide 10: GJB2 mutations and non-syndromic hearing loss
GJB2 mutations and non-syndromic hearing loss >100 GJB2 recessive mutations described to date, with SENS-601 designed as a single- construct approach across GJB2 variants Severity of hearing loss correlates with the degree of GJB2 loss of function. Copyright by Sensorion 2026. All Rights Reserved 10
Slide 11: Construct design
Construct design AAV-DJ capsid with broad tropism for cochlear supporting cells. Cassette combining a constitutive 5' promoter, the CX26 coding sequence and a proprietary regulatory sequence in the 3' UTR, yielding functional 26 kDa CX26 proteins. Selective. Sequence complementary to miR-183, presen
Slide 12: Surgical delivery approach
Surgical delivery approach Dual-fenestration technique combines two familiar procedures, cochlear implantation and stapedotomy, and is designed to minimize overpressure and backflow. Designed to maximize vector distribution and target cell exposure along the full length of the cochlea, allowing wide
Slide 13: SENS-601 Efficiently Transduces NHP Cochlea
SENS-601 Efficiently Transduces NHP Cochlea Injection of SENS-601 (Flag surrogate), at the NHP equivalent effective dose, leads to strong transgene detection in the cochlea of NHP from base to apex Flag signal within the CX26 network was quantified across the different compartments of interest and t
Slide 14: Tropism and selectivity to CX26-expressing target cells in NHP
Tropism and selectivity to CX26-expressing target cells in NHP Three weeks after a single intracochlear injection: No transgene expression extensive transduction of the supporting cells that in the sensory hair cells naturally express GJB2 observed along the tonotopic axis of the cochlea. No transge
Slide 15: Cx26 knock-out mouse model
Cx26 knock-out mouse model Exclusive conditional knock-out model; conditional design circumvents the embryonic lethality of complete biallelic GJB2 loss. Early inactivation in utero, while the inner ear develops, reproduces the pathophysiology of DFNB1A, the most Severe to profound hearing loss comm
Slide 16: Hearing restoration in Cx26 knock-out mice
Hearing restoration in Cx26 knock-out mice Hearing improvement observed as early as three weeks after injection, across all tested frequencies. Demonstrated across multiple dose levels, with a therapeutic dose selected for further development. Replicated across multiple research and development manu
Slide 17: Cochlear CX26 levels are normalized by SENS-601 in the cKO1 model
Cochlear CX26 levels are normalized by SENS-601 in the cKO1 model – outer sulcus CX26 levels quantification CX26 signal mean intensity level (A.U.) Vehicle injected controls SENS-601 – 0.3X dose injected mutants Vehicle injected mutants SENS-601 – 1X dose injected mutants Tonotopic and dose-dependen
Slide 18: The CX26 network itself is rescued, not only the level of expression
The CX26 network itself is rescued, not only the level of expression CX26 Mainnetwork metricsmetrics CX26 network CX26 network metrics are improved in multiple cochlear structures and cell type … Association with ABR outcome Branch-point density r=0.4826 Branch density r=0.4718 Network length r=0.46
Slide 19: Restoration of functional CX26 gap junctions in vitro
Restoration of functional CX26 gap junctions in vitro Propidium iodide, in red, is a fluorescent dye HeLa DH cells lacking CX26, or carrying a Cells transduced with SENS-601 took up dye that cannot cross intact cell membranes, so mutated CX26, showed no dye transfer. across all three variants tested
Slide 20: Toxicology findings in NHP and mice
Toxicology findings in NHP and mice Non-human primate studies Mouse studies Design. Unilateral intracochlear administration. Three groups: vehicle, low Design. Intravenous administration. Three groups: vehicle, low dose, high dose, high dose. Two cohorts: 3 months and 6 months. dose. Three cohorts:
Slide 21: HearConnex will evaluate SENS-601 safety and efficacy
HearConnex will evaluate SENS-601 safety and efficacy, with first patient dosing anticipated in early 2027 Open-label, multicenter Phase I/II trial to assess the safety, tolerability and efficacy of intracochlear administration of SENS-601 at escalating doses and the injection system. Trial objectiv
Slide 22: HearConnex is designed to allow fast transition to pivotal trial
HearConnex is designed to allow fast transition to pivotal trial HearConnex Phase I/II Open-Label Trial Design PX: patient number X. DMC: Data Monitoring Committee. Part 1 uses unilateral administration, Part 2 bilateral administration. Patients age: Part 1 (Dose escalation): ≥ 6 months to ≤ 31 mont
Slide 23: Summary
Summary Activity to date Near-term milestones CTA cleared in France, submitted in Canada US IND and Australia CTA submission Congenital onset; Fast Track granted in France Expected by end of 2026 Phase I/II trial initiation Natural history study running Dosing of the first patient targeted by early
Slide 24: Sensorion core development capabilities for SENS-601
Sensorion core development capabilities for SENS-601 01 02 03 04 05 Differentiated Validated surgical Manufacturing Clinical execution HL strategic biological approach technique experience connectivity Pan-GJB2 approach, Dual-fenestration CDMO partnership for Operational experience Global network of
Slide 25: Corporate Overview
CORPORATE OVERVIEW Team, governance and financial position 25
Slide 26: Executive team
Executive team Fred Chereau Laurent Desire Stephanie Filipe Bernd Schmidt Chief Executive Officer Head of Preclinical Head of Business Ops and Chief Technical Officer Portfolio Management At Sensorion since 2026. Previously At Sensorion since 2020. Previously At Sensorion since 2020. Previously At S
Slide 27: Board of directors
Board of directors Amit Munshi Chairman of the Board, USA Khalil Barrage USA Federico Mingozzi* USA Julien Miara France Aniz Girach* UK Sofinnova Partners Represented by Cédric Moreau, France Represented by Eric de la Redmile Group Health Opportunities* Represented by Florian Reinaud, France Fortell
Slide 28: Scientific advisory board
Scientific advisory board Pr Christine Petit Pr Alain Fischer Dr Robert Dow Chair of the SAB. Professor, Institut Professor, Collège de France, Chief Development Officer, Scendea, Pasteur, Hearing Institute/ Institut France UK reConnect, France Pr Paul Avan Dr Diane Lazard Dr Hernán López-Schier Hea
Slide 29: Financial position
Financial position Cash and equivalents & short term deposits Cash runway €88 million Year-end 2027 As of 30 June 2026 Shareholder base Blue-chip healthcare specialist investors, alongside strategic investor Sanofi Including Invus, Sofinnova Partners, Redmile Group, Cormorant Asset Management and Co
Slide 30: Current status and expected milestones
Current status and expected milestones Program H2 2026 2027 SENS-601: congenital CTA approved in France Dosing of the first patient targeted by early 2027 Canadian CTA submitted onset US IND and Australia CTA submission Clinical data generation expected throughout 2027 SENS-601: pediatric Preclinica
Slide 31: Sensorion at a glance
Sensorion at a glance On a mission to enable people with inner ear hearing disorders to live life with unlimited connections. SENS-601 is in the clinic, on a Potential to disrupt a treatment Deep domain expertise and key global development path landscape with no approved partners to strengthen our s
Slide 32: Appendix
APPENDIX Copyright by Sensorion 2026. All Rights Reserved 32
Slide 33: CX26 biology in detail
CX26 biology in detail GJB2, which encodes CX26, is naturally expressed in the non- sensory supporting cells of the cochlea. CX26 is the predominant connexin in the cochlea; its heteromeric or heterotypic hexamers form gap junctions. GJB2 is absent in sensory hair cells, where functional gap junctio
Slide 34: Construct design in detail
Construct design in detail The transgene cassette comprises a promoter, a CX26 coding sequence and a proprietary regulatory sequence in the 3’ untranslated region. The regulatory sequence is transcribed into mRNA complementary to miR-183, a small non-coding RNA occurring robustly in sensory inner ha
Slide 35: Gap junction permeability assay
Gap junction permeability assay c.35delG p.M34T p.V37I Untransduced HeLa DH cells are highly stable during electrophysiological testing, making them the industry standard for gap junction assays. c.35delG is a truncating mutation associated with severe-to- profound hearing loss; p.M34T and p.V37I ar
Slide 36: SENS-401: an oral otoprotectant candidate
SENS-401: an oral otoprotectant candidate Orphan drug designation Orally available small molecule, the (R)-enantiomer of azasetron, with a EMA1 and FDA2 dual mechanism: 5-HT₃ receptor antagonism with calcineurin- inhibitory activity. Pediatric investigation plan Designed to protect inner-ear sensory
Slide 37: SENS-401 data package across three indications
SENS-401 data package across three indications Hearing preservation after Cisplatin-induced ototoxicity Sudden sensorineural hearing cochlear implantation loss Positive Phase IIa: 25 of 28 randomized Phase IIa completed: 47 randomized Phase IIb (AUDIBLE-S): 115 randomized patients implanted Complete
Slide 38: The hearing loss spectrum and standard of care
The hearing loss spectrum and standard of care Hearing aids amplify sound, but do not restore the Cochlear implants bypass the sensory epithelium Access and clarity are both required for a good clarity lost when the cochlear supporting cell entirely, and are indicated only toward the severe- outcome